combine RNA interference technology being developed by both companies,and provide MDRNA with much-needed cash.
—Brightleaf, a Westwood, MA-based maker of software for assembling legal documents, raised $2.9 million of a planned $3 million equity-based round led by returning investor, Foundry Group.
—Watertown, MA’s Selecta Biosciences, a vaccine developer, pulled in $15 million in Series C funding, led by new lead investor OrbiMed Advisors. The new funding, which includes existing backers Polaris Venture Partners, Flagship Ventures, NanoDimension, and Leukon Investments, will go to making nanoparticles, components of a new generation of vaccines. Selecta didn’t actively seek out the latest round, which comes on top of $15 million the company wrapped up in February 2009.
—Crimson Hexagon, a Cambridge company focused on monitoring brand reputations on the Web and social media, completed a $2 million Series A-2 funding round, and pulled in a new CEO, Scott Centurino, who came from Mobile Messaging Solutions. The new financing comes from Golden Seeds, Beacon Angels, New York Angels, CT Angel Investor Forum, and Zelkova Ventures.
—Dyax (NASDAQ: [[ticker:DYAX]]), a Cambridge drug developer, added to the $51.8 million it raised in a 17 million share stock offering last month, priced at $3.25 per share. In a sale that closed on Monday, underwriter Jefferies & Company exercised its over-allotment option to purchase an additional 2.55 million shares of common stock at $3.25 per share, bringing the total net proceeds for the offering to about $59.6 million.
—Online video hosting company Brightcove raised $12 million in Series D funding, led by Accel Partners and General Catalyst Partners. The venture capital will go to new products, expansions in Asia and Europe, R&D, and possible mergers and acquisitions, the company said in its corporate blog. Existing investors, including AOL, Hearst, AllianceBernstein, Maverick Capital, and Brookside Capital, also contributed to the round.
